Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver; VA Office of Research and Development
• Collaborator: VA Office of Research and Development
• Treatments: 3-(2,4-dimethoxybenzylidene)anabaseine

Criteria

Inclusion Criteria:

• Schizophrenia

• Currently treated with neuroleptic drugs

Exclusion Criteria:

• Treatment with clozapine;

• Head injury or neurological condition;

• Cardiovascular disease;

• Substance abuse or dependence, including nicotine